Epoetin alfa (Eprex) and quality of life.
Several recently published clinical trials in anaemic patients with cancer provide convincing evidence that the quality of life of such patients is considerably impaired and that a significant improvement in quality of life can be achieved if their anaemia is corrected by treatment with recombinant erythropoietin (epoetin alfa, Eprex). Findings of some of the major studies are summarised in this issue. These summaries have been prepared to make the findings more accessible to busy clinicians who may not have time to read longer reports in specialist journals but who need to understand the important clinical implications of this research.
Littlewood
Tim
T
Department of Haematology, John Radcliffe Hospital, Oxford, UK.
D000740:Anemia / Q000150:complications / Q000628:therapy*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011788:Quality of Life; D011994:Recombinant Proteins; D006113:United Kingdom
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa